1. A Standardized Supplement For The Treatment of Psoriasis

4. TNF -  Atherosclerosis COPD Rheumatoid Arthritis Psoriasis IBD Ankylosing Spondylitis Diseases related to TNF - 

7. Botanical name: Sphaeranthus indicus English Name: East Indian Globe-Thistle Indian Name: Gorakhmundi A much branched, strongly-scented annual with winged stem and the wings toothed. Flowers compound heads, globose avoid, glandular hairy Traditional uses: Time tested herb and widely used in Ayurveda Used in Indigestion, Bronchitis, Spleen diseases, Elephantiasis, Inflammatory conditions of pelvis in women, Piles, Asthma, Treatment of glandular swelling in the neck Sphaeranthus indicus Fruiting & flowering Inflorescence head Herb in nature Pharmacognostically standardized & Extraction process developed to obtain holistic extract

9. Safety Check Efficacy Check Quality Check Certificate of Analysis with Specification

11. Tinefcon inhibits LPS-induced TNF-  release in mice ** Bar graph: Mean + SEM; * p<0.0005 Student’s T-test Tinefcon inhibits LPS-induced IL-1  release in mice In vivo activity

12. In vivo activity – Histopathology Protects cartilage degradation in joints

13. Tinefcon reduces the severity of experimental colitis in mice In vivo studies – Ulcerative Colitis model Rectal Bleeding 0.00 0.25 0.50 0.75 1.00 N D Sp Rectal Bleeding Index % Weight Loss -10 -5 0 5 10 15 20 25 30 N D Sp % Weight Loss During Study Disease Activity Index 0 2 4 6 8 10 N D Sp DAI Score Colon Length 0 4 8 12 N D Sp Colon Length (cm) Stool Consistency 0 1 2 3 N D Sp Stool Consistency Index N: Naïve mice D: DSS-fed mice Sp: DSS-fed mice + Tinefcon (400 mg/kg p.o.) * * * *

14. Naïve Well preserved architecture Tinefcon (400 mg/kg p.o.) DSS Complete loss of architecture Protection from mucosal erosions Tinefcon treated mice reduces DSS-induced alterations in mucosal architecture and colonic damage In vivo studies – Ulcerative Colitis model (Histopathology analysis)

15. Tinefcon extract reduces development and progression of atherosclerosis in LDLr-deficient mice Bar graph: Mean + SEM; * p<0.05 vs vehicle, ANOVA Atherosclerotic lesion quantitation In vivo studies – Atherosclerosis model Veh Feno Tinefcon Tinefcon 100 mg/kg 100 mg/kg 300mg/kg -26% -22% -21% * * *

16. **p<0.01 by ANOVA (Dunnett’s Test) Tinefcon Inhibits Atherosclerosis Progression in Hyperlipidemic Hamsters In vivo studies – Atherosclerosis model Vehicle Fenofibrate Tinefcon (100 mpk) (200 mpk) Vehicle Fenofibrate Tinefcon (100 mpk) (200 mpk) Vehicle Fenofibrate Tinefcon Mean 0.5025 0.0834 0.2736 STD 0.2151 0.1131 0.1482 SEM 0.06487 0.03577 0.04686 % Change -84 -45

18. Psoriasis - Prevalence Worldwide estimated 125m people suffer from psoriasis Sources; International Federation Psoriasis Association (IFPA) 2007 ~ 5% ~ 3 % ~ 2.6 % ~ 2.0 % ~ 2.5 % ~ 1 % ~ 1 % ~ 1.5 % ~ 2 %

21. Study Design ENROLMENT (N = 74) WASH OUT 2 wks- TOPICAL Rx WASH OUT 4 wks- PUVA Rx RANDOMIZATION 1:1:1 Tinefcon 2.8 g/day Placebo Tinefcon 1.4 g/day STUDY COMPLETED (N = 48) E M O L L I E N T S

23. 0 10 20 30 40 50 60 70 Placebo 1.4g 2.8g Treatment % Patients 75% improvement in PASI score Effect of Tinefcon in Psoriasis Patients

24. BASELINE AFTER 12 WEEKS OF TREATMENT Photographic evidence Case 1 Case 2

31. Histo- pathology Analysis Gene expression PASI 75% Score Epidermal thickness Tinefcon Tinefcon (An Efficacious Phytopharmaceutical)